|
1
|
Adam R, Pascal G, Castaing D, Azoulay D,
Delvart V, Paule B, Levi F and Bismuth H: Tumor progression while
on chemotherapy: A contraindication to liver resection for multiple
colorectal metastases? Ann Surg. 240:1052–1064. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giuliante F, Ardito F, Ferrero A,
Aldrighetti L, Ercolani G, Grande G, Ratti F, Giovannini I,
Federico B, Pinna AD, et al: Tumor progression during preoperative
chemotherapy predicts failure to complete 2-stage hepatectomy for
colorectal liver metastases: Results of an Italian multicenter
analysis of 130 patients. J Am Coll Surg. 219:285–294. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adam R, Wicherts DA, de Haas RJ, Ciacio O,
Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D:
Patients with initially unresectable colorectal liver metastases:
Is there a possibility of cure? J Clin Oncol. 27:1829–1835. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ardito F, Vellone M, Cassano A, De Rose
AM, Pozzo C, Coppola A, Federico B, Giovannini I, Barone C, Nuzzo G
and Giuliante F: Chance of cure following liver resection for
initially unresectable colorectal metastases: Analysis of actual
5-year survival. J Gastrointest Surg. 17:352–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baba K, Oshita A, Kohyama M, Inoue S,
Kuroo Y, Yamaguchi T, Nakamura H, Sugiyama Y, Tazaki T, Sasaki M,
et al: Successful treatment of conversion chemotherapy for
initially unresectable synchronous colorectal liver metastasis.
World J Gastroenterol. 21:1982–1988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cauchy F, Aussilhou B, Dokmak S, Fuks D,
Gaujoux S, Farges O, Faivre S, Lepillé D and Belghiti J:
Reappraisal of the risks and benefits of major liver resection in
patients with initially unresectable colorectal liver metastases.
Ann Surg. 256:746–754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Devaud N, Kanji ZS, Dhani N, Grant RC,
Shoushtari H, Serrano PE, Nanji S, Greig PD, McGilvray I, Moulton
CA, et al: Liver resection after chemotherapy and tumour downsizing
in patients with initially unresectable colorectal cancer liver
metastases. HPB (Oxford). 16:475–480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Folprecht G, Gruenberger T, Bechstein W,
Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J,
Lang H, Trarbach T, et al: Survival of patients with initially
unresectable colorectal liver metastases treated with
FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary
concept (CELIM study). Ann Oncol. 25:1018–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Galizia G, De Vita F, Lieto E, Zamboli A,
Morgillo F, Castellano P, Mabilia A, Auricchio A, Renda A,
Ciardiello F and Orditura M: Conversion chemotherapy followed by
hepatic resection in colorectal cancer with initially unresectable
liver-limited metastases. Oncol Rep. 30:2992–2998. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huiskens J, van Gulik TM, van Lienden KP,
Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A,
Mol L, Molenaar IQ, et al: Treatment strategies in colorectal
cancer patients with initially unresectable liver-only metastases,
a study protocol of the randomised phase 3 CAIRO5 study of the
Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 15:3652015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lam VW, Laurence JM, Johnston E, Hollands
MJ, Pleass HC and Richardson AJ: A systematic review of two-stage
hepatectomy in patients with initially unresectable colorectal
liver metastases. HPB (Oxford). 15:483–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maeda Y, Shinohara T, Nagatsu A, Futakawa
N and Hamada T: Long-term outcomes of conversion hepatectomy for
initially unresectable colorectal liver metastases. Ann Surg Oncol.
23:S242–S248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dindo D, Demartines N and Clavien PA:
Classification of surgical complications: A new proposal with
evaluation in a cohort of 6336 patients and results of a survey.
Ann Surg. 240:205–213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clavien PA, Barkun J, de Oliveira ML,
Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J,
Slankamenac K, Bassi C, et al: The Clavien-Dindo classification of
surgical complications: Five-year experience. Ann Surg.
250:187–196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lam VW, Spiro C, Laurence JM, Johnston E,
Hollands MJ, Pleass HC and Richardson AJ: A systematic review of
clinical response and survival outcomes of downsizing systemic
chemotherapy and rescue liver surgery in patients with initially
unresectable colorectal liver metastases. Ann Surg Oncol.
19:1292–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahashi T, Shibata Y, Tojima Y, Tsuboi
K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma
T, et al: Multicenter phase II study of modified FOLFOX6 as
neoadjuvant chemotherapy for patients with unresectable liver-only
metastases from colorectal cancer in Japan: ROOF study. Int J Clin
Oncol. 18:335–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masi G, Loupakis F, Pollina L, Vasile E,
Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi
F, et al: Long-term outcome of initially unresectable metastatic
colorectal cancer patients treated with 5-fluorouracil/leucovorin,
oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery
of metastases. Ann Surg. 249:420–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gruenberger T, Bridgewater J, Chau I,
Alfonso García P, Rivoire M, Mudan S, Lasserre S, Hermann F,
Waterkamp D and Adam R: Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in
patients with initially unresectable liver metastases from
colorectal cancer: The OLIVIA multinational randomised phase II
trial. Ann Oncol. 26:702–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai
SY, Ye QH, Yu Y, Xu B, Qin XY and Xu J: Randomized controlled trial
of cetuximab plus chemotherapy for patients with KRAS wild-type
unresectable colorectal liver-limited metastases. J Clin Oncol.
31:1931–1938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ychou M, Rivoire M, Thezenas S, Quenet F,
Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E,
Ducreux M, et al: A randomized phase II trial of three intensified
chemotherapy regimens in first-line treatment of colorectal cancer
patients with initially unresectable or not optimally resectable
liver metastases. The METHEP trial. Ann Surg Oncol. 20:4289–4297.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaguchi T, Matsumoto H, Yasutome M, Mori
T and Takahashi K: Phase I/II study of irinotecan, UFT and
leucovorin with hepatic arterial infusion using 5-FU in colorectal
cancer patients with unresectable liver metastases. Cancer
Chemother Pharmacol. 67:629–635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kemeny NE, Melendez FD, Capanu M, Paty PB,
Fong Y, Schwartz LH, Jarnagin WR, Patel D and D'Angelica M:
Conversion to resectability using hepatic artery infusion plus
systemic chemotherapy for the treatment of unresectable liver
metastases from colorectal carcinoma. J Clin Oncol. 27:3465–3471.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujimoto Y, Akasu T, Yamamoto S, Fujita S
and Moriya Y: Long-term results of hepatectomy after hepatic
arterial infusion chemotherapy for initially unresectable hepatic
colorectal metastases. J Gastrointest Surg. 13:1643–1650. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nuzzo G, Giuliante F, Ardito F, Vellone M,
Pozzo C, Cassano A, Giovannini I and Barone C: Liver resection for
primarily unresectable colorectal metastases downsized by
chemotherapy. J Gastrointest Surg. 11:318–324. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takahashi S, Konishi M, Kinoshita T,
Gotohda N, Kato Y, Saito N, Sugito M and Yoshino T: Predictors for
early recurrence after hepatectomy for initially unresectable
colorectal liver metastasis. J Gastrointest Surg. 17:939–948. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beppu T, Miyamoto Y, Sakamoto Y, Imai K,
Nitta H, Hayashi H, Chikamoto A, Watanabe M, Ishiko T and Baba H:
Chemotherapy and targeted therapy for patients with initially
unresectable colorectal liver metastases, focusing on conversion
hepatectomy and long-term survival. Ann Surg Oncol. 21 Suppl
3:S405–S413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayashi H, Beppu T, Sakamoto Y, Miyamoto
Y, Yokoyama N, Higashi T, Nitta H, Hashimoto D, Chikamoto A and
Baba H: Prognostic value of Ki-67 expression in conversion therapy
for colorectal liver-limited metastases. Am J Cancer Res.
5:1225–1233. 2015.PubMed/NCBI
|
|
31
|
Popescu I and Alexandrescu ST: Surgical
options for initially unresectable colorectal liver metastases. HPB
Surg. 2012:4540262012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Figueras J, Lopez-Ben S, Alsina M, Soriano
J, Hernandez-Yagüe X, Albiol M, Guardeño R, Codina-Barreras A and
Queralt B: Preoperative treatment with bevacizumab in combination
with chemotherapy in patients with unresectable metastatic
colorectal carcinoma. Clin Transl Oncol. 15:460–466. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okamura Y, Takeda S, Fujii T, Sugimoto H,
Nomoto S and Nakao A: Prognostic significance of postoperative
complications after hepatectomy for hepatocellular carcinoma. J
Surg Oncol. 104:814–821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khuri SF, Henderson WG, DePalma RG, Mosca
C, Healey NA and Kumbhani DJ: Participants in the VA National
Surgical Quality Improvement Program: Determinants of long-term
survival after major surgery and the adverse effect of
postoperative complications. Ann Surg. 242:326–343. 2005.PubMed/NCBI
|
|
35
|
Hirai T, Yamashita Y, Mukaida H, Kuwahara
M, Inoue H and Toge T: Poor prognosis in esophageal cancer patients
with postoperative complications. Surg Today. 28:576–579. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mynster T, Christensen IJ, Moesgaard F and
Nielsen HJ: Effects of the combination of blood transfusion and
postoperative infectious complications on prognosis after surgery
for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group.
Br J Surg. 87:1553–1562. 2000. View Article : Google Scholar : PubMed/NCBI
|
